a 2022

Prognostic factors for survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage

ROHAN, Tomáš, Peter MATKULČÍK, Michal UHER, Barbora ČECHOVÁ, Matej STRAKA et. al.

Basic information

Original name

Prognostic factors for survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage

Authors

ROHAN, Tomáš (203 Czech Republic, guarantor, belonging to the institution), Peter MATKULČÍK (703 Slovakia, belonging to the institution), Michal UHER (203 Czech Republic), Barbora ČECHOVÁ (203 Czech Republic, belonging to the institution), Matej STRAKA (703 Slovakia, belonging to the institution), Vlastimil VÁLEK (203 Czech Republic, belonging to the institution), Tomáš KLAIL (203 Czech Republic, belonging to the institution), Dominika ROSINOVÁ (703 Slovakia, belonging to the institution) and Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution)

Edition

CIRSE 2022, 2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30224 Radiology, nuclear medicine and medical imaging

Country of publisher

Spain

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14110/22:00126760

Organization unit

Faculty of Medicine

DOI

UT WoS

000852601000002

Keywords in English

biliary cancer; percutaneous transhepatic drainage; risk factors; survival

Tags

Změněno: 3/4/2023 10:30, Mgr. Tereza Miškechová

Abstract

V originále

Purpose: To identify factors affecting survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage (PTD). Materials and Methods: This single-centre retrospective study included 233 consecutive patients undergoing PTD for cancer of biliary origin at a tertiary referral hospital from 1/2005 to 12/2019. Cox regression model was used to assess variables related to overall survival after initial PTD. The variables included demographic (age, sex), imaging (mass forming vs. infiltrative, size of mass forming tumor, localisation, Bismuth-Corlette classification in hilar tumors, presence of metastasis), laboratory (bilirubin, liver enzymes and inflammatory markers before and 3-7 days after the procedure, and hemoglobin, thrombocytes, urea and creatinine before the procedure), and treatment parameters of PTD (number of percutaneous drains, presence and number of implanted metal stents, and performance of endobiliary radiofrequency ablation). Results: In multivariate analysis, age (HR 1.23 per 10 years, p=0.005), location (gallbladder cancer HR 2.82 and p<0.001 compared to hilar cancer; common bile duct cancer HR 0.64 and p=0.049; papilla Vateri HR 0.31 and p=0.002), size of the mass (HR 1.07 per cm, p=0.005), level of bilirubin (≥250 umol/L with HR 1.57 and p=0.009) and hemoglobin (≤110 g/L with HR 1.93 and p=0.001) were shown to be significant factors affecting survival in patients with cancer of biliary origin since first PTD. Conslusion: Age, tumour location, mass size, bilirubin and hemoglobin levels before the first PTD have been shown to be significant prognostic factors for survival in patients with cancer of biliary origin treated with PTD.

Links

MUNI/A/1388/2021, interní kód MU
Name: Význam radiologických intervencí a pokročilých zobrazovacích metod v diagnostice a léčbě pacientů s maligním onemocněním
Investor: Masaryk University
NU21-08-00561, research and development project
Name: Využití ireverzibilní elektroporace a vysokofrekvenční ireverzibilní elektroporace k léčbě okluzí metalických stentů
Investor: Ministry of Health of the CR, Subprogram 1 - standard